)
)
)
3Helix
3Helix has developed a first-in-class targeted therapeutic platform leveraging bioACTIVE Collagen Hybridizing Peptides (CHPs) that selectively target damaged collagen in the extracellular matrix (ECM). Our technology delivers cell-binding sites in the required triple-helical confirmation to directly modulate cellular health in complex diseases, with capabilities currently crossing inflammation/autoimmune, fibrosis, drug delivery, and cancer.
Address
Salt Lake CityUT
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)